Click here for Inflectra® (infliximab) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
What is a biosimilar
The future of biosimilars
Considerations for biologic switching
A biosimilar is a biologic product that is approved based on a demonstration that shows that it is highly similar to an approved biologic product, known as the reference product.1-3
Biosimilars are developed to be highly similar to the reference product with no clinically meaningful differences in terms of quality, efficacy and safety.1-3
Biosimilars can support a more sustainable healthcare system,4-7 expanding treatment options and enabling cost savings8 without compromising safety or efficacy.1-3,9
Potential benefits of biosimilars for patients, payers and providers include:4-6
Learn about the safety profile of Inflectra in patients with rheumatoid arthritis
Learn about the dosing and administration of Inflectra in patients with rheumatoid arthritis
Inflammatory bowel disease
Infliximab mechanism of action
Support & Resources
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020